Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.National Institute of Mental Health (NIMH) has granted nearly $700,000 to Omeros to develop antibodies against orphan G protein-coupled receptors (GPCRs) associated with neurological disorders using antibody discovery (DTLacO) platform.
Subscribe to our email newsletter
Omeros’ proprietary DTLacO technology is an ex vivo antibody discovery platform that pairs an engineered chicken B-cell line with antibody selection strategies and also has antibody repertoire from which specific antibodies are selected basing on the therapy requirement.
Omeros chairman and chief executive officer Gregory Demopulos said Omeros DTLacO platform can generate antibodies that target a wide range of diseases, including multiple types of cancer.
”With respect to our orphan GPCR program, the DTLacO platform nicely complements our proprietary cellular redistribution assay that, to date, has identified small molecules that functionally interact with 42 orphan GPCRs,” Demopulos added.
Demopulos further said DTLacO platform provides different approach to discover and develop drugs for the receptors that are resistive to high-throughput CRA approach.